attia glp 1 Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025) 320 – AMA 64: New

Mature or fully differentiated osteoblasts, which express osteocalcin (OCN), acquire functions to mineralize the matrix and produce hardened bone

clinical diagnosis of MCI or AD using standardized diagnosis

NO generated by eNOS regulates vascular tone by inhibiting smooth muscle contraction and platelet aggregation

BODIPY- C1-27A labelling of GSTO1 was decreased in C1-27 -treated tumours compared with the control group (Fig

Sterile technique: Use new sterile insulin syringes for each injection

only GLP-1 agonist with dedicated cardiovascular outcomes data in obesity population Maximizing weight loss beyond GLP-1 monotherapy Survodutide Phase 2 data suggest up to 19% weight loss